Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials

Clinical Lung Cancer

Volumn 11, Issue 2, 2010, Pages 126-131

  Zinner, Ralph G ^a   Novello, Silvia ^b   Peng, Guangbin ^c   Herbst, Roy ^a   Obasaju, Coleman ^c   Scagliotti, Giorgio ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c Lilly Corporate Center   (United States)

Author keywords

Cisplatin; Nonsquamous histology; Oxaliplatin; Predictive factors

Indexed keywords

CARBOPLATIN; OXALIPLATIN; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 77952497362     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.017     Document Type: Article

References (33)

1. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26:42-47
2. Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999; 26:68-73.
3. Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999; 10:1175-1179
4. Kindler HL. Pemetrexed in pancreatic cancer. Semin Oncol 2002; 29:49-53.
5. O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005; 6:143-149
6. Paz-Ares L, Ciruelos E, Garcia-Carbonero R, et al. Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol 2002; 29:69-75.
7. Spielmann M, Martin M, Namer M, et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51.
8. Thodtmann R, Sauter T, Weinknecht S, et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003; 21:353-358
9. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29:3-17.
10. Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19:437-443
11. Takimoto CH. New Antifolates: Pharmacology and Clinical Applications. Oncologist 1996; 1:68-81.
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597
13. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
14. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440
15. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253-263
16. Kubota K, Niho S, Enatsu S, et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009; 4:1530-1536
17. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596
18. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11:690-696
19. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 2005; 104:2449-2456
20. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
22. Grønberg BH, Bremnes RM, Fløtten Ø, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:3217-3224
23. Hirsch F, Sperafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008; 3:1468-1481
24. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-13795
25. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14:1059-1064
26. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I non-small-cell lung cancer. Cancer 2008; 112:2765-2773
27. Socinski M, Smit E, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. Paper presented at: the 2008 Annual Meeting of the American Society of Clinical Oncology; May 30-Jun 3, 2008; Chicago, IL.
28. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353
29. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123:226S-43S.
30. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
31. Treat J, Edelman M, Belani C, et al. Outcomes were similar across histological subgroups in a three arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3(suppl 4):S285 (abstract 139).
32. Pimentel F, von Pawel J, Martin R, et al. Resource utilization by non-small cell lung cancer histology: results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin. J Clin Oncol 2008; 26(15 supp):448s (abstract 8097).
33. Strauss G, Jemal A, McKenna M, et al. The epidemic of smoking-related adenocarcinoma of the lung: The role of the tobacco industry and filtered and low-tar cigarettes. Paper presented at: The 12th World Conference on Lung Cancer; September 2-6, 2007; Seoul, Korea. Abstract PRS-01.